Sameem Abedin, MD
Hematology & Oncology · Milwaukee, WINPI 1063641157
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,512 of the $87,502 with a category attached, or 72.6%. 16 manufacturers reported payments, led by Incyte Corporation at 33.9% of the total. Among hematology & oncology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $883.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$30K
- Servier Pharmaceuticals LLC$13K
- Sanofi$10K
- Helsinn Healthcare SA$10K
- Amgen$6K
- AbbVie$5K
- plus $15K from 10 others
Across 241 payments — averaging $13,274 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$957K
- Incyte Corporation$706K
- Pfizer$488K
- National Marrow Donor Program$410K
- Janssen Research & Development, LLC$221K
- Astellas Pharma Global Development$199K
- plus $217K from 3 others
What the payments were for
- Consulting fees$63,51273%
- Speaking & faculty fees$5,5506%
- Travel & lodging$15,57918%
- Food & beverage$2,8513%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 31 | $29,622 |
| Servier Pharmaceuticals LLC | 18 | $12,573 |
| Sanofi | 6 | $10,470 |
| Helsinn Healthcare SA | 8 | $9,579 |
| Amgen | 1 | $5,841 |
| AbbVie | 9 | $4,890 |
| Jazz Pharmaceuticals Inc. | 6 | $4,313 |
| Agios Pharmaceuticals, Inc. | 9 | $4,103 |
| Stemline Therapeutics Inc. | 1 | $2,750 |
| Daiichi Sankyo Inc. | 2 | $2,060 |
| National Marrow Donor Program | 3 | $539 |
| AstraZeneca | 1 | $525 |
| Medexus Pharma, Inc. | 1 | $169 |
| Sanofi-aventis U.S. LLC | 1 | $43 |
| Avion Pharmaceuticals | 1 | $15 |
| Pfizer | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,502 in reported general payments places this provider in the 90th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 56 | $715,115 |
| RezurockBelumosudil Mesylate | 11 | $280,992 |
| VenclextaVenetoclax | 23 | $210,057 |
| CalquenceAcalabrutinib Maleate | 17 | $124,289 |
| Tacrolimus | 13 | $1,530 |
| Acyclovir | 68 | $1,276 |
| Fluconazole | 26 | $1,114 |
| Ursodiol | 18 | $1,039 |
| ValacyclovirValacyclovir Hcl | 13 | $789 |
| Dexamethasone | 17 | $169 |
| Prednisone | 46 | $77 |
| Allopurinol | 14 | $46 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $45 |
| Azithromycin | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $29,622 | $715,11556 claims |
| Sanofi-aventis U.S. LLCRezurock | $43 | $280,99211 claims |
| AbbVieVenclexta | $4,890 | $210,05723 claims |
| AstraZenecaCalquence | $525 | $124,28917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 hematology & oncology providers in Wisconsin.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.